Doctors have treated 5 patients with B cell acute lymphoblastic leukaemia (B-ALL) using T Cells genetically modified to target CD19, a protein found on the surface of B-cells.
Cytokine elevations directly correlated to tumor burden at the time of CAR-modified T cell infusions, with some patients requiring steroid therapy to ameliorate cytokine-mediated toxicities.
Further information is available from MSKCC on both the research results and the ongoing clinical trial.